Alkermes (ALKS)
Alkermes on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
17.8M
Short interest
settlement 2026-09-30
6.3
Days to cover
-4.4 days vs prior
70.8%
Short share of volume
2026-10-09
566
Fails to deliver
settlement 2026-08-24
Wed 21 Oct
Next earnings
estimated date
-$3.8M
Insider flow, 90 days
0 buys, 8 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in ALKS is 17,821,179 shares, up 3,103,775 shares over the last month. Over the last 48 readings it ranged from 10,562,324 shares (13 June 2025) to 21,843,844 shares (31 December 2025). At the reported average volume of 2.8M shares a day that is 6.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/alks" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 17,821,179 | +17.6% | 2,839,345 | 6.28 |
| 2026-09-15 | 15,156,775 | +3.0% | 1,416,869 | 10.70 |
| 2026-08-31 | 14,717,404 | -0.3% | 1,248,178 | 11.79 |
| 2026-08-14 | 14,761,342 | +2.5% | 1,448,036 | 10.19 |
| 2026-07-31 | 14,406,911 | -4.1% | 1,866,095 | 7.72 |
| 2026-07-15 | 15,017,743 | -14.0% | 1,648,870 | 9.11 |
| 2026-06-30 | 17,464,944 | -2.8% | 3,631,213 | 4.81 |
| 2026-06-15 | 17,962,751 | +3.5% | 1,899,270 | 9.46 |
| 2026-05-29 | 17,355,226 | -5.0% | 2,054,158 | 8.45 |
| 2026-05-15 | 18,277,684 | -7.5% | 2,420,484 | 7.55 |
| 2026-04-30 | 19,760,435 | +0.4% | 1,574,220 | 12.55 |
| 2026-04-15 | 19,684,219 | +3.5% | 2,410,781 | 8.17 |
| 2026-03-31 | 19,013,418 | -7.7% | 3,242,646 | 5.86 |
| 2026-03-13 | 20,600,815 | +13.2% | 2,184,528 | 9.43 |
| 2026-02-27 | 18,196,226 | +2.1% | 1,975,718 | 9.21 |
| 2026-02-13 | 17,817,507 | -6.2% | 1,522,737 | 11.70 |
| 2026-01-30 | 18,996,649 | -12.3% | 2,425,456 | 7.83 |
| 2026-01-15 | 21,666,003 | -0.8% | 2,073,206 | 10.45 |
| 2025-12-31 | 21,843,844 | +9.0% | 1,516,821 | 14.40 |
| 2025-12-15 | 20,033,904 | +6.4% | 1,728,095 | 11.59 |
| 2025-11-28 | 18,829,721 | +8.9% | 2,082,226 | 9.04 |
| 2025-11-14 | 17,295,320 | +8.8% | 3,643,182 | 4.75 |
| 2025-10-31 | 15,896,950 | +10.4% | 2,713,089 | 5.86 |
| 2025-10-15 | 14,402,055 | -5.3% | 1,706,717 | 8.44 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of ALKS volume is 70.8%, up 14.0 points over the last five sessions. Over the last 30 readings it ranged from 29.5% (10 September 2026) to 70.8% (9 October 2026). The latest reading sits at the top of that range. The latest reading is 22.5 points above the 30-session average of 48.3%, on 809K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 573K | 809K | 70.8% | 0 |
| 2026-10-08 | 963K | 1.4M | 69.2% | 0 |
| 2026-10-07 | 567K | 974K | 58.2% | 0 |
| 2026-10-06 | 401K | 641K | 62.6% | 0 |
| 2026-10-05 | 789K | 1.2M | 63.4% | 368 |
| 2026-10-02 | 481K | 847K | 56.8% | 0 |
| 2026-10-01 | 344K | 793K | 43.3% | 147 |
| 2026-09-30 | 262K | 577K | 45.4% | 40 |
| 2026-09-29 | 496K | 1.4M | 35.2% | 0 |
| 2026-09-28 | 321K | 827K | 38.8% | 197 |
| 2026-09-25 | 375K | 967K | 38.8% | 0 |
| 2026-09-24 | 396K | 1.1M | 36.3% | 25,528 |
| 2026-09-23 | 403K | 1.0M | 40.3% | 0 |
| 2026-09-22 | 500K | 899K | 55.6% | 0 |
| 2026-09-21 | 1.0M | 1.8M | 58.2% | 20 |
| 2026-09-18 | 647K | 1.1M | 60.1% | 0 |
| 2026-09-17 | 253K | 596K | 42.5% | 0 |
| 2026-09-16 | 338K | 690K | 49.1% | 0 |
| 2026-09-15 | 599K | 937K | 64.0% | 93 |
| 2026-09-14 | 383K | 669K | 57.3% | 246 |
| 2026-09-11 | 138K | 281K | 48.9% | 157 |
| 2026-09-10 | 127K | 431K | 29.5% | 206 |
| 2026-09-09 | 143K | 443K | 32.2% | 0 |
| 2026-09-08 | 191K | 548K | 34.8% | 0 |
| 2026-09-04 | 166K | 395K | 42.0% | 17 |
| 2026-09-03 | 113K | 300K | 37.9% | 22 |
| 2026-09-02 | 136K | 362K | 37.6% | 0 |
| 2026-09-01 | 170K | 403K | 42.3% | 425 |
| 2026-08-31 | 215K | 455K | 47.3% | 65 |
| 2026-08-28 | 231K | 462K | 50.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 24 August 2026, the fails-to-deliver balance in ALKS is 566 shares, down 2,702 shares over the last settlement date. Over the last 30 readings it ranged from 6 shares (18 June 2026) to 229,448 shares (1 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-24 | 566 | $48.33 | $27K |
| 2026-08-06 | 3,268 | $49.61 | $162K |
| 2026-08-04 | 84 | $49.53 | $4K |
| 2026-08-03 | 19,365 | $48.99 | $949K |
| 2026-07-29 | 20 | $50.50 | $1K |
| 2026-07-20 | 17 | $52.72 | $896 |
| 2026-07-01 | 229,448 | $52.40 | $12.0M |
| 2026-06-26 | 15 | $52.83 | $792 |
| 2026-06-25 | 52 | $50.45 | $3K |
| 2026-06-18 | 6 | $44.51 | $267 |
| 2026-06-15 | 60 | $44.28 | $3K |
| 2026-06-12 | 1,184 | $44.92 | $53K |
| 2026-06-11 | 27,674 | $43.84 | $1.2M |
| 2026-06-09 | 71 | $42.45 | $3K |
| 2026-06-08 | 2,354 | $42.80 | $101K |
| 2026-06-04 | 45 | $42.76 | $2K |
| 2026-05-28 | 166 | $38.09 | $6K |
| 2026-05-26 | 1,631 | $36.80 | $60K |
| 2026-05-21 | 317 | $36.98 | $12K |
| 2026-05-19 | 1,467 | $37.19 | $55K |
| 2026-05-15 | 10,764 | $38.36 | $413K |
| 2026-05-07 | 3,757 | $35.32 | $133K |
| 2026-05-05 | 182,241 | $34.17 | $6.2M |
| 2026-04-24 | 1,032 | $33.91 | $35K |
| 2026-04-20 | 69,054 | $34.53 | $2.4M |
| 2026-04-08 | 46,394 | $33.02 | $1.5M |
| 2026-04-07 | 13 | $34.08 | $443 |
| 2026-04-01 | 19,192 | $35.36 | $679K |
| 2026-03-31 | 34,000 | $30.15 | $1.0M |
| 2026-03-23 | 29 | $28.15 | $816 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at ALKS reported 8 open-market sells worth $3.8M in the last 90 days and no open-market buys. Latest filing: Reed Joshua (SVP, Chief Financial Officer) on 2026-10-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-08 | Reed Joshua | SVP, Chief Financial Officer | Tax withholding | 4K | $40.11 | $163K | 5K |
| 2026-10-08 | Reed Joshua | SVP, Chief Financial Officer | Option exercise | 9K | price not stated in the filing | not stated | 9K |
| 2026-10-02 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $41.03 | $83K | 221K |
| 2026-09-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $48.01 | $98K | 223K |
| 2026-09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9K | $46.99 | $423K | 65K |
| 2026-09-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $24.59 | $123K | 74K |
| 2026-08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell | 664 | $49.65 | $33K | 102K |
| 2026-08-17 | Nichols Christian Todd | SVP, Chief Commercial Officer | Sell | 7K | $49.19 | $340K | 103K |
| 2026-08-03 | snyderman nancy lynn MD | Director | Sell | 44K | $50.35 | $2.2M | 15K |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise | 17K | $46.72 | $772K | 60K |
| 2026-08-03 | snyderman nancy lynn MD | Director | Option exercise | 28K | $46.72 | $1.3M | 43K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9K | $48.58 | $437K | 69K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $24.59 | $120K | 78K |
| 2026-08-03 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 104 | $19.34 | $2K | 73K |
| 2026-08-03 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $48.58 | $99K | 225K |
| 2026-07-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $54.03 | $110K | 227K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 700 | $52.13 | $36K | 73K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 8K | $51.46 | $427K | 74K |
| 2026-07-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $19.34 | $97K | 82K |
| 2026-06-12 | Wright Christopher I | Director | Sell | 2K | $45.10 | $90K | 26K |
| 2026-06-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $43.05 | $88K | 230K |
| 2026-06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9K | $41.67 | $375K | 77K |
| 2026-06-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $19.34 | $97K | 86K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Sell | 16K | $42.36 | $687K | 8K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise | 13K | $19.34 | $248K | 24K |
| 2026-05-29 | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Option exercise | 3K | $20.03 | $68K | 11K |
| 2026-05-21 | Cooke Shane | Director | Tax withholding | 3K | $36.95 | $118K | 107K |
| 2026-05-21 | Cooke Shane | Director | Option exercise | 6K | price not stated in the filing | not stated | 110K |
| 2026-05-21 | GAYNOR RICHARD | Director | Option exercise | 6K | price not stated in the filing | not stated | 37K |
| 2026-05-21 | GAYNOR RICHARD | Director | Tax withholding | 1K | $36.95 | $55K | 36K |
| 2026-05-21 | LAURENCIN CATO T | Director | Tax withholding | 1K | $36.95 | $55K | 34K |
| 2026-05-21 | LAURENCIN CATO T | Director | Option exercise | 6K | price not stated in the filing | not stated | 35K |
| 2026-05-21 | Lurker Nancy | Director | Option exercise | 6K | price not stated in the filing | not stated | 20K |
| 2026-05-21 | Lurker Nancy | Director | Tax withholding | 1K | $36.95 | $55K | 18K |
| 2026-05-21 | MCKEON BRIAN P | Director | Tax withholding | 1K | $36.95 | $55K | 39K |
| 2026-05-21 | MCKEON BRIAN P | Director | Option exercise | 6K | price not stated in the filing | not stated | 40K |
| 2026-05-21 | snyderman nancy lynn MD | Director | Tax withholding | 1K | $36.95 | $55K | 15K |
| 2026-05-21 | snyderman nancy lynn MD | Director | Option exercise | 6K | price not stated in the filing | not stated | 17K |
| 2026-05-21 | Wilson Frank Anders | Director | Tax withholding | 1K | $36.95 | $55K | 36K |
| 2026-05-21 | Wilson Frank Anders | Director | Option exercise | 6K | price not stated in the filing | not stated | 37K |
| 2026-05-21 | Wright Christopher I | Director | Tax withholding | 1K | $36.95 | $55K | 28K |
| 2026-05-21 | Wright Christopher I | Director | Option exercise | 6K | price not stated in the filing | not stated | 29K |
| 2026-05-04 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $33.20 | $68K | 232K |
| 2026-05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9K | $33.40 | $301K | 81K |
| 2026-05-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $19.34 | $97K | 90K |
| 2026-04-11 | Lurker Nancy | Director | Option exercise | 4K | price not stated in the filing | not stated | 14K |
| 2026-04-11 | Lurker Nancy | Director | Tax withholding | 901 | $33.36 | $30K | 14K |
| 2026-04-06 | Gaffin David Joseph | EVP, CLO, Alkermes, Inc. | Sell | 2K | $34.57 | $70K | 234K |
| 2026-04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Sell | 9K | $35.51 | $320K | 85K |
| 2026-04-01 | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Option exercise | 5K | $19.34 | $97K | 94K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON28 Form 144 notices on file for ALKS worth $9.7M at the prices reported; 7 in the last 90 days worth $3.8M. Latest: Gaffin David Joseph filed on 2026-10-02 to sell 2,034 shares ($83K) from 2026-10-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-02 | Gaffin David JosephOfficer | 2K | $83K | 0.001% | 2026-10-02 | Merrill Lynch |
| 2026-09-03 | Gaffin David JosephOfficer | 2K | $98K | 0.001% | 2026-09-03 | Merrill Lynch |
| 2026-09-01 | Hopkinson Craig C.Officer | 9K | $423K | 0.005% | 2026-09-01 | Merrill Lynch |
| 2026-08-17 | Nichols Christian ToddOfficer | 8K | $373K | 0.005% | 2026-08-17 | Merrill Lynch |
| 2026-08-03 | snyderman nancy lynn MDOfficer | 44K | $2.2M | 0.027% | 2026-08-03 | Merrill Lynch |
| 2026-08-03 | Gaffin David JosephOfficer | 2K | $99K | 0.001% | 2026-08-03 | Merrill Lynch |
| 2026-08-03 | Hopkinson Craig C.Officer | 9K | $437K | 0.005% | 2026-08-03 | Merrill Lynch |
| 2026-07-06 | Gaffin David JosephOfficer | 2K | $110K | 0.001% | 2026-07-06 | Merrill Lynch |
| 2026-07-01 | Hopkinson Craig C.Officer | 9K | $464K | 0.005% | 2026-07-01 | Merrill Lynch |
| 2026-06-12 | Wright Christopher IOfficer | 2K | $90K | 0.001% | 2026-06-12 | Merrill Lynch |
| 2026-06-04 | Gaffin David JosephOfficer | 2K | $88K | 0.001% | 2026-06-04 | Merrill Lynch |
| 2026-06-01 | Hopkinson Craig C.Officer | 9K | $375K | 0.005% | 2026-06-01 | Merrill Lynch |
| 2026-05-04 | Gaffin David JosephOfficer | 2K | $68K | 0.001% | 2026-05-04 | Merrill Lynch |
| 2026-05-01 | Hopkinson Craig C.Officer | 9K | $301K | 0.005% | 2026-05-01 | Merrill Lynch |
| 2026-04-06 | Gaffin David JosephOfficer | 2K | $70K | 0.001% | 2026-04-06 | Merrill Lynch |
| 2026-04-01 | Hopkinson Craig C.Officer | 9K | $320K | 0.005% | 2026-04-01 | Merrill Lynch |
| 2026-03-03 | Gaffin David JosephOfficer | 2K | $61K | 0.001% | 2026-03-03 | Merrill Lynch |
| 2026-03-02 | Nichols Christian ToddOfficer | 6K | $180K | 0.004% | 2026-03-02 | Merrill Lynch |
| 2026-03-02 | Gaffin David JosephOfficer | 2K | $60K | 0.001% | 2026-03-02 | Merrill Lynch |
| 2026-03-02 | Hopkinson Craig C.Officer | 9K | $267K | 0.005% | 2026-03-02 | Merrill Lynch |
| 2026-02-02 | Cooke ShaneOfficer | 61K | $2.1M | 0.037% | 2026-02-02 | Merrill Lynch |
| 2026-02-02 | Hopkinson Craig C.Officer | 9K | $305K | 0.005% | 2026-02-02 | Merrill Lynch |
| 2026-01-08 | Hopkinson Craig C.Officer | 5K | $150K | 0.003% | 2026-01-08 | Merrill Lynch |
| 2026-01-02 | Hopkinson Craig C.Officer | 4K | $112K | 0.002% | 2026-01-02 | Merrill Lynch |
| 2025-12-03 | Hopkinson Craig C.Officer | 4K | $112K | 0.002% | 2025-12-03 | Merrill Lynch |
| 2025-12-01 | Hopkinson Craig C.Officer | 4K | $117K | 0.002% | 2025-12-01 | Merrill Lynch |
| 2025-11-03 | Hopkinson Craig C.Officer | 9K | $273K | 0.005% | 2025-11-03 | Merrill Lynch |
| 2025-10-15 | Hopkinson Craig C.Officer | 9K | $284K | 0.005% | 2025-10-15 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of ALKS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Baker Bros. Advisors LP at 6.1% of the class (10,012,267 shares), filed 2026-02-17 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 2 | T. Rowe Price Associates, Inc.investment adviser | 4.7M | 2.8% | 2026-03-31 |
| 2026-04-28 | 13G | Vanguard Portfolio Managementinvestment adviser | 9.6M | 5.8% | 2026-03-31 |
| 2026-04-28 | 13G | Vanguard Capital Managementinvestment adviser | 8.7M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 16 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G | Baker Bros. Advisors LPinvestment adviser, partnership | 10.0M | 6.1% | 2025-12-31 |
| 2026-02-17 | 13G | Baker Bros. Advisors (GP) LLCparent holding company, other entity | 10.0M | 6.1% | 2025-12-31 |
| 2026-02-17 | 13G | Julian C. Bakerparent holding company, individual | 10.0M | 6.1% | 2025-12-31 |
| 2026-02-17 | 13G | Felix J. Bakerparent holding company, individual | 10.0M | 6.1% | 2025-12-31 |
| 2025-11-10 | 13G | STATE STREET CORPORATIONparent holding company | 8.5M | 5.2% | 2025-09-30 |
13F holders
Tracked managers holding ALKS at their latest 13F. JSON7 of the 30 tracked managers held ALKS at their latest 13F, $597.7M in total at quarter-end prices. Renaissance Technologies is the largest at $338.5M (0.5% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 6.5M | $338.5M | 0.47% | +301K |
| Citadel Advisors | 2026-06-30 | 1.6M | $86.2M | 0.01% | -596K |
| D. E. Shaw & Co. | 2026-06-30 | 1.3M | $68.7M | 0.03% | +602K |
| Two Sigma Investments | 2026-06-30 | 1.0M | $54.4M | 0.04% | +258K |
| Fisher Asset Management | 2026-06-30 | 419K | $22.0M | 0.01% | +29K |
| Millennium Management | 2026-06-30 | 320K | $16.7M | 0.01% | new |
| AQR Capital Management | 2026-06-30 | 213K | $11.2M | 0.00% | -171K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Alkermes reported revenue of $496.0M, up 27.0% from the same quarter a year earlier, and net income of $501K (0.00 diluted EPS). In FY 2025 it generated $520.8M of operating cash flow. As of 2026-06-30, cash was $511.5M against $1.52B of debt.
- Cash
- $511.5M
- Debt
- $1.52B
- Equity
- $1.81B
- Total assets
- $4.39B
- Shares outstanding
- 167,763,272
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $496.0M | $501K | 0.1% | 0.00 |
| Q1 FY 2026 | 2026-03-31 | $392.9M | -$66.5M | -16.9% | -0.40 |
| Q4 FY 2025derived | 2025-12-31 | $384.5M | $49.3M | 12.8% | n/a |
| Q3 FY 2025 | 2025-09-30 | $394.2M | $82.8M | 21.0% | 0.49 |
| Q2 FY 2025 | 2025-06-30 | $390.7M | $87.1M | 22.3% | 0.52 |
| Q1 FY 2025 | 2025-03-31 | $306.5M | $22.5M | 7.3% | 0.13 |
| Q4 FY 2024derived | 2024-12-31 | $430.0M | $146.5M | 34.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $378.1M | $92.4M | 24.4% | 0.55 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1.48B | $241.7M | $520.8M | $40.4M | n/a | n/a |
| FY 2024 | 2024-12-31 | $1.56B | $367.1M | $439.1M | $33.5M | $200.3M | n/a |
| FY 2023 | 2023-12-31 | $1.66B | $355.8M | $401.4M | $48.0M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.11B | -$158.3M | $21.0M | $38.3M | n/a | n/a |
| FY 2021 | 2021-12-31 | $1.17B | -$48.2M | $101.7M | $28.0M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-23 from the cover page.
What this page is
Alkermes in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Alkermes (ALKS), SEC CIK 1520262, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-24.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2025-10-22.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 1520262Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
- ARQTArcutis Biotherapeutics
Datasets
Frequently Asked Questions
How much of ALKS is sold short?
What is ALKS's daily short volume?
Does ALKS have fails to deliver?
Are ALKS insiders buying or selling?
Have ALKS insiders filed to sell?
Who owns 5% or more of ALKS?
What did ALKS report last quarter?
Which tracked 13F managers own ALKS?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.